Jones Day is advising OGEL GmbH, the majority shareholder of Biotest AG, Germany, in connection with the decision of CREAT Group, China, to make a voluntary public takeover offer to all Biotest shareholders. Pursuant to the announcement, the transaction values Biotest at €1.3 billion enterprise value. Biotest is a global company that supplies plasma protein products and biotherapeutic drugs.

For additional information about this matter, please contact: Johannes Perlitt
Client(s): OGEL GmbH
Practice(s): M&A, Capital Markets, Life Sciences, Private Equity
Office(s): Frankfurt